UPDATE: Barclays Starts Jazz Pharmaceuticals (JAZZ) at Overweight; Use Share Weakness as Opportunity

June 21, 2012 7:50 AM EDT
Get Alerts JAZZ Hot Sheet
Price: $115.57 -1.47%

Rating Summary:
    28 Buy, 4 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 35 | Down: 31 | New: 11
Trade JAZZ Now!
Join SI Premium – FREE
(Updated - June 21, 2012 3:38 PM EDT)

Barclays initiates coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with an Overweight. PT $60.00.

Analyst, Douglas D. Tsao, feels that despite some possible pressure down the road from generic companies, Jazz Pharma offers one of the best options for Specialty Pharma. Tsao cites the current share price, which he feels under-appreciates the cohesiveness of the Xyrem franchise.

Bears think a generic may be available as soon as 2015, but Tsao thinks it will be pushed back closer to 2018. FY12 EPS estimate moved to $4.70 and FY13 to $5.58.

For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.

Shares of Jazz Pharmaceuticals closed at $46.03 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst EPS Change, New Coverage

Related Entities


Add Your Comment